Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
International Journal of Peptide Research and Therapeutics is Scopus-indexed (Q2, CiteScore 5.3), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Science and Business Media B.V..
Checked against the index lists dated .
ISSN 1573-3149Verify ISSN ↗1573-3904Verify ISSN ↗
Publisher: Springer Science and Business Media B.V.
Cost to publish: About US$3,890 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Analytical Chemistry | 67 / 160 | 58th | Q2 |
| Drug Discovery | 69 / 161 | 57th | Q2 |
| Biochemistry | 207 / 448 | 53rd | Q2 |
| Bioengineering | 90 / 168 | 46th | Q3 |
| Molecular Medicine | 96 / 179 | 46th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2005–present (also 1996–2002), best quartile Q2, CiteScore 5.3.
International Journal of Peptide Research and Therapeutics is Q2 in Analytical Chemistry (rank 67 of 160), Q2 in Drug Discovery (rank 69 of 161) and Q2 in Biochemistry (rank 207 of 448), by CiteScore 2025. It is ranked in 5 subject areas in all.
International Journal of Peptide Research and Therapeutics is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.3, which places it in quartile Q2 at the 58th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.532, quartile Q2, with an H-index of 53.
The publisher lists an article processing charge of about US$3,890 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
International Journal of Peptide Research and Therapeutics is published by Springer Science and Business Media B.V. Its print ISSN is 1573-3149 and its online ISSN is 1573-3904.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
International Journal of Peptide Research and Therapeutics has an h-index of 58 and a 2-year mean of 2.31 citations per paper (OpenAlex). Its Scopus CiteScore is 5.3, quartile Q2. On 2-year citations it ranks #88 of 154 Scopus journals in Analytical Chemistry.
International Journal of Peptide Research and Therapeutics published 115 papers in 2025; its busiest recent year was 2019 with 201. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2025–2026), authors are most often from India (37%), China (12.3%) and Iran (7.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 4 retracted papers are recorded (1.8 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.